ALX2004 vs BPI-361175
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
ALX2004
Developed by ALX Oncology Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07085091 (registry estimate)
No aligned efficacy figure on record for this race.
BPI-361175
Developed by Betta Pharmaceuticals Co.
NCT05329298 · Phase 1/2 · status unknown
This is an open-label, non-randomized phase 1/2 dose-escalation and expansion study in which every participant received BPI-361175 with no placebo or active comparator, and no blinding was used. Results have not been posted, and because the design never included a controlled comparison, it cannot demonstrate a controlled treatment effect regardless.
Next expected readout: January 2028 · NCT05393466 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALX2004 | BPI-361175 |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- ALX2004
- —Not reported
- BPI-361175
- —Not reported
OS, median
- ALX2004
- —Not reported
- BPI-361175
- —Not reported
ORR
- ALX2004
- —Not reported
- BPI-361175
- —Not reported
Duration of response, median
- ALX2004
- —Not reported
- BPI-361175
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALX2004: no structured comparison results are available for Non-Small Cell Lung Cancer.
BPI-361175: no structured comparison results are available for Non-Small Cell Lung Cancer.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALX2004's landscape · BPI-361175's landscape